November 10, 2025 5:45pm

What did I write on Friday, “I’m still maintaining to BUY the dips …”

This a.m., I wrote: “No one likes counting: 8 negative closes in the last 10 sessions with another week of earnings = positive moves”

Pre-open Indication Scoring: 7 Hits and 1 Miss

RMi collects, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision

Never leave an investor uninformed! 

 

Indexes “roared” on Monday after Senate lawmakers took critical steps to end the U.S. government shutdown.

Monday’s RMi pre-open: A friendlier week and market? … https://www.regmedinvestors.com/articles/14188

The past, present and future values of RMi’s analysis sheds light on the cell and gene therapy’s (C&GT) sector’s “current” acrobatics

 

Monday: The Dow closed UP +381.53 points or +0.81%, the S&P closed UP +103.63 points or +1.54% while the Nasdaq closed UP +522.637 points or +2.27%

  • Theme of the session: shutdown melts … slowly

Henry’omics: We need to more than consider the macro-economic environment to comprehend the micro re “our” universe of cell and gene therapy (C&GT) sector

  • A procedural measure that allows other votes on the agreement was approved by a minimum of 60 yes votes, after 8 senators in the Democratic caucus broke with party leadership to support the deal.

Monday’s (my) 40-company covered sector’s advance/decline line opened positive with 33 incliners, 7 decliners and 0 flats ending with a positive close of 26 incliners, 14 decliners and 0 flat

Metrics:  Monday …

  • The RUT was up +22.84 points or +0.94%,
  • The IWM was up +2.43 or +1.01%;
  • The IBB was up =1.82 points or +1.15%,
  • The NBI was up +67.64 points or +1.28%;
  • The XLV was up +1.14 points or +0.78%,
  • The XBI was up +1.13 points or +1.04% … while
  • The VIX was down -1.45 points or -7.60% at 17.63

 

Q4 – November - 2 positive and 4 negative closes

  • October -1 neutral, 11 positive and 12 negative closes

 

Monday Closing UP (10 of 26) 

  • Vertex (VRTX +$11.73 after Friday’s -$6.78),
  • IQVIA Holdings (IQV +$2.59 after Friday’s -$0.41),
  • BioNTech (BNTX +$1.93),
  • Ultragenyx Pharmaceuticals (RARE +$1.31),
  • Arrowhead Pharma (ARWR +$0.62),
  • Mesoblast (MESO +$0.60),
  • AxoGen (AXGN +$0.43 after Friday’s -$0.42),
  • BioLife Solutions (BLFS +$0.36 after Friday’s -$1.09),
  • Cellectis SA (CLLS +$0.36 after Friday’s +$0.06),
  • Entrada Therapeutics (TRDA +$0.35),

Flat (0)

Monday’s Closing DOWN (10 of 14): 

  • Ionis Pharmaceuticals (IONS -$4.01 after Friday’s -$0.55),
  • uniQure NV (QURE -$1.64 after Friday’s +$0.28),
  • Alnylam Pharmaceuticals (ALNY -$1.00 after Friday’s +$2.21),
  • Wave Life Sciences (WVE -$0.81),
  • Supernus Therapeutics (SUPN -$0.62 after Friday’s -$1.24),
  • Beam Therapeutics (BEAM -$0.56 after Friday’s -$0.94),
  • CRISPR Therapeutics (CRSP -$0.54 after Friday’s -$1.49),
  • Capricor Therapeutics (CAPR -$0.37),
  • Sarepta Therapeutics (SRPT -$0.36),
  • Prime Medicine (PRME -$0.28 after Friday’s -$0.37)

 

The Bottom Line: More of the … WHYs

The cell and gene therapy sector was vulnerable to activate an upside move.

Indexes also experienced the rally as daylights was shed on the government shutdown …

  • The S&P 500 climbed 1.5% clawing-back nearly all its drop from last week, which was its 1st weekly loss in 4.
  • The Dow rose +0.81%, and
  • The Nasdaq jumped 2.3% for its best day since May.

C&GT sector equities also continued to be leveled as Q3 earnings continued to release

 

I see mid-week an interruption coming … from earnings expectation and consensus always considering earnings season LPS (loss-per-share).

  • Sector Q3 earnings … Agenus (AGEN), Capricor Therapeutics (CAPR) and Wave Life Sciences (WVE) on 11/10
  • Think about it; one of the biggest problems with the cell and gene therapy sector’s share pricing is …  99% of them have no earnings! Revenue from collaborations and runways have become indications of sustainability.
  • I believe earnings per share (EPS) estimates need to be revised along with the response to their share pricing declines upon their release to shake-off pipeline uncertainties
  • Meeting earnings expectation and/or missing consensus will deem share pricing outcomes
  • As earnings evolve, I think it's important to focus on fundamentals, advancing clinical catalysts, “runways” and sector company’s capacity/ability to finance

Expectation: Fate Therapeutics (FATE) is expected to post a Q3 loss of $0.29 per share in its upcoming report, which represents a year-over-year change of +27.5%. Revenues are expected to be $0.85 million, down 72.3% from the year-ago quarter.

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

New  month, November: understand the “flow” …

This week:

  • 11/10 - Monday closed positive with 26 positive, 14 negative and 0 flats

Last week:

  • 11/7 – Friday closed negative with 16 positive, 24 negative and 0 flat
  • 11/6 – Thursday closed negative with 15 positive, 24 negative and 1 flat
  • 11/5 - Wednesday closed positive with 20 positive, 18 negative and 2 flats
  • 11/4 – Tuesday closed negative with 10 positive, 30 negative and 0 flat
  • 11/3 – Monday closed negative with 10 positive, 26 negative and 4 flats

 

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:   

  • Monday: Vertex (VRTX), IQVIA Holdings (IQV) and BioNTech (BNTX)
  • Friday: Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) and Compass Therapeutics (CMPX)

The worst three (3) in the session:

  • Monday: Ionis Pharmaceuticals (IONS), uniQure NV (QURE) and Alnylam Pharmaceuticals (ALNY),
  • Friday: Vertex (VRTX), Intellia Therapeutics (NTLA) and CRISPR Therapeutics (CRSP)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.